ATE421974T1 - Chemokine mutanten, die als chemokine antagonisten wirken - Google Patents

Chemokine mutanten, die als chemokine antagonisten wirken

Info

Publication number
ATE421974T1
ATE421974T1 AT02791832T AT02791832T ATE421974T1 AT E421974 T1 ATE421974 T1 AT E421974T1 AT 02791832 T AT02791832 T AT 02791832T AT 02791832 T AT02791832 T AT 02791832T AT E421974 T1 ATE421974 T1 AT E421974T1
Authority
AT
Austria
Prior art keywords
chemokine
mutants
action
antagonists
chemokine antagonists
Prior art date
Application number
AT02791832T
Other languages
German (de)
English (en)
Inventor
Amanda Proudfoot
Marie Kosco-Vilbois
Jeffrey Shaw
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Application granted granted Critical
Publication of ATE421974T1 publication Critical patent/ATE421974T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/521Chemokines
    • C07K14/523Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT02791832T 2001-12-17 2002-12-16 Chemokine mutanten, die als chemokine antagonisten wirken ATE421974T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01000761 2001-12-17

Publications (1)

Publication Number Publication Date
ATE421974T1 true ATE421974T1 (de) 2009-02-15

Family

ID=8176112

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02791832T ATE421974T1 (de) 2001-12-17 2002-12-16 Chemokine mutanten, die als chemokine antagonisten wirken

Country Status (10)

Country Link
US (1) US7553483B2 (https=)
EP (1) EP1458756B1 (https=)
JP (1) JP2005525089A (https=)
AT (1) ATE421974T1 (https=)
AU (1) AU2002358144B2 (https=)
CA (1) CA2468790A1 (https=)
DE (1) DE60231057D1 (https=)
ES (1) ES2320743T3 (https=)
IL (1) IL162600A0 (https=)
WO (1) WO2003051921A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2305573T3 (es) * 2002-12-23 2008-11-01 Laboratoires Serono Sa Uso de metantes de quimiocinas cc ccl5/rantes contra transtornos del higado.
ATE322506T1 (de) * 2004-01-19 2006-04-15 Ares Trading Sa Verfahren zur reinigung von in bakterien exprimierten proteinen
US8445442B2 (en) 2007-04-26 2013-05-21 University Of Vermont And State Agricultural College CCL18 and CCL3 methods and compositions for detecting and treating cancer
US8012474B2 (en) 2007-08-02 2011-09-06 Nov Immune S.A. Anti-RANTES antibodies
WO2010071610A1 (en) * 2008-12-19 2010-06-24 Agency For Science, Technology And Research (A*Star) Severe chikungunya biomarkers
EP2380975A1 (de) * 2010-04-22 2011-10-26 Scil Proteins GmbH Verfahren zur Herstellung von rekombinantem Thrombin
US9717777B2 (en) 2010-05-05 2017-08-01 Rappaport Family Institute For Research In The Medical Sciences Use of CCL1 in therapy
US9352000B2 (en) * 2010-05-05 2016-05-31 Rappaport Family Institute For Research In The Medical Sciences Use of CCL1 in therapy
EP3307330B1 (en) * 2015-06-15 2021-03-10 New York University Method of treatment using oncolytic viruses
WO2017077062A1 (en) * 2015-11-05 2017-05-11 Ludwig-Maximilians-Universität München A peptide derived from human neutrophile peptide 1
KR102682118B1 (ko) 2016-04-29 2024-07-08 주식회사유한양행 Ccl3 변이체를 포함하는 융합 단백질 및 이의 용도
CA3233658A1 (en) 2021-10-06 2023-04-13 Ursula Gompels Novel immune regulator

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI943024L (fi) 1991-12-23 1994-06-22 British Bio Technology Kantasoluja estävät proteiinit
FI972433A0 (fi) * 1994-12-08 1997-06-06 Glaxo Group Ltd Rantes-peptidi ja fragmentteja sekä tätä sisältäviä tulehduksen hoitoon soveltuvia koostumuksia
AU5137698A (en) 1996-12-05 1998-06-29 Kyowa Hakko Kogyo Co. Ltd. Novel dna, novel protein, and novel antibody
AU5383498A (en) * 1996-12-05 1998-06-29 Human Genome Sciences, Inc. Human chemokine beta-13
EP0906954A1 (en) 1997-09-29 1999-04-07 Applied Research Systems ARS Holding N.V. Amino-terminal truncated c-c chemokines as chemokine antagonist
DK1431391T3 (da) 1997-12-23 2005-12-19 San Raffaele Centro Fond RANTES-mutanter og terapeutiske anvendelser heraf
JPH11243960A (ja) * 1998-03-06 1999-09-14 Shionogi & Co Ltd ヒトcc型ケモカインエオタキシン3
ES2205849T3 (es) * 1998-07-22 2004-05-01 Osprey Pharmaceuticals Limited Conjugados para tratar alteraciones inflamatorias y asociadas con daños tisulares.
AU5617900A (en) * 1999-06-17 2001-01-09 Robert C. Gallo Chimeric chemokine-antigen polypeptides and uses therefor
EP2206720A1 (en) 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albumin fusion proteins
UA77950C2 (en) 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis

Also Published As

Publication number Publication date
CA2468790A1 (en) 2003-06-26
EP1458756B1 (en) 2009-01-28
ES2320743T3 (es) 2009-05-28
US7553483B2 (en) 2009-06-30
WO2003051921A1 (en) 2003-06-26
DE60231057D1 (de) 2009-03-19
AU2002358144B2 (en) 2008-10-02
IL162600A0 (en) 2005-11-20
EP1458756A1 (en) 2004-09-22
AU2002358144A1 (en) 2003-06-30
US20050220757A1 (en) 2005-10-06
JP2005525089A (ja) 2005-08-25

Similar Documents

Publication Publication Date Title
IL214607A0 (en) 2,4-pyrimidinedinediamine compounds and their use in the manufacture of medicaments for the treatment of autoimmune disases
ATE421974T1 (de) Chemokine mutanten, die als chemokine antagonisten wirken
DE60143292D1 (de) Varianten des menschlichen Koagulationsfaktors VII
SG145698A1 (en) Methods of treating or preventing autoimmune diseases with 2,4- pyrimidinediamine compounds
AU2003291998A8 (en) Method and compositions for identifying anti-hiv therapeutic compounds
ATE458057T1 (de) Varianten der faktor-vii- oder -viia-gla-domäne
CA2395343A1 (en) Use of acid-stable proteases in animal feed
ECSP093601A (es) Proteínas derivadas del virus del síndrome de mancha blanca y sus usos
MXPA03001984A (es) Variantes de factor vii de coagulacion humano.
EP1357909A4 (en) ANTAGONISTS OF IL-8 RECEPTORS
MXPA02012743A (es) Moleculas tipo il-17 y usos de las mismas.
GB0111186D0 (en) Novel compounds
UA86345C2 (ru) Применение остеопротегерина для лечения и/или предотвращения фиброза
WO2001064889A3 (en) Tnf-alpha variants for the treatment of tnf-alpha related disorders
MXPA05005202A (es) Vacuna.
YU102503A (sh) Kondenzovani pirimidinski dhfr inhibitori kao antibakterijska sredstva
EP1169340A4 (en) lantibiotic
SE0302304D0 (sv) Novel compounds
MY133845A (en) Il-8 receptor antagonists
AP1548A (en) Il-8 Receptor Antagonists.
MXPA03004539A (es) Luciferasas aisladas y uso de las mismas.
SG146640A1 (en) Isolated photoprotein mtclytin, and use thereof
WO2001064165A3 (en) Il-8 receptor antagonists
MY143477A (en) Il-8 receptor antagonists
ATE394117T1 (de) Verwendung von cc-chemokine ccl5/rantes mutanten zur behandlung von lebererkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties